Feiba (Factor Viii Inhibitor Bypassing Fraction)

Feiba (Factor VIII Inhibitor Bypassing Fraction) is a medication used to manage bleeding episodes in patients with hemophilia who have inhibitors. This intravenous treatment helps control bleeding by bypassing the need for Factor VIII.

Feiba is primarily used to manage bleeding episodes in patients with hemophilia A or B who have developed inhibitors to Factor VIII or IX. These inhibitors can make standard treatments less effective, and Feiba helps bypass this issue to control bleeding. It is often used in situations where other treatments are not sufficient.

Feiba works by providing a temporary clotting factor to help manage bleeding episodes. Common effects may include localized reactions at the injection site, such as redness or swelling. Some patients may also experience systemic reactions like fever or chills.

Feiba should be administered under the supervision of a healthcare professional. It is important to follow the prescribed dosage and administration guidelines to minimize the risk of adverse effects. Patients should inform their healthcare provider about any allergies or medical conditions before using Feiba.

Feiba may interact with other medications, particularly those that affect blood clotting. It is important to discuss all current medications with a healthcare provider before starting Feiba. Additionally, patients should avoid activities that increase the risk of bleeding while using this medication.